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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the efficacy and safety of celecoxib as an add-on treatment to standard care for people with schizophrenia.
B A C K G R O U N D
Description of the condition
Schizophrenia is a serious mental illness characterised by distor-
tions of thinking and perception (positive symptoms) and cogni-
tion (cognitive symptoms), as well as inappropriate or blunted af-
fect (negative symptoms) (WHO2016). Affecting around0.3% to
0.7% of people worldwide at some point in their life, schizophre-
nia typically has an onset in early adulthood; it may have a con-
tinuous course, or it may be episodic with either a progressive or a
stable deficit (WHO 2016; van Os 2009). Schizophrenia has high
human and financial costs; people diagnosed with schizophrenia
tend to live 12 to 15 years less than the general population (van
Os 2009). This raised mortality is mainly linked to poor physical
health, which results from increased exposure to risk factors such
as poor diet, low levels of exercise, smoking and obesity, together
with suicide (van Os 2009).
Current treatments for schizophrenia are only partially effective,
with up to 30% of people having treatment-resistant positive
symptoms, and the majority having poor long-term social and
occupational functioning (Gaughran 2018). Antipsychotic medi-
cations, traditionally categorised into typical (or first generation)
and atypical (or second generation), are the mainstay treatment
for schizophrenia (Tandon 2011). They are effective for treat-
ing the positive symptoms of schizophrenia, but are not as effec-
tive for cognitive and negative symptoms (El-Sayed El-Sisi 2016;
Sangani 2017). Antipsychotics can cause debilitating, sometimes
irreversible side effects (Girgis 2014). First-generation antipsy-
chotics are primarily associated with movement disorders and hy-
perprolactinaemia, as well as muscarinic side effects such as dry
mouth and urinary retention, while second-generation antipsy-
chotics are associated with adverse events that include Type 2 di-
abetes mellitus, weight gain, dizziness and somnolence (Sangani
2017). Therefore additional treatments are often given alongside
antipsychotics to help improve clinical efficacy or alleviate side
effects, or both.
The aetiology of schizophrenia is unclear but there are several
risk factors associated with the development of the illness that
include both genetic and environmental factors. Recent research
also suggests that schizophrenia could be linked to immune system
activation in the brain (Schwieler 2015; Upthegrove 2014a). This
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has led to the consideration of anti-inflammatory agents as a new
avenue for much needed therapies.
Description of the intervention
Celecoxib is a non-steroidal anti-inflammatory medication
(NSAID) that is relatively safe and inexpensive (Riedel 2005).
Celecoxib is a specific cyclo-oxygenase-2 (COX-2) inhibitor and
may be safer than other NSAIDs in terms of its side-effect pro-
file, particularly on the gastrointestinal tract (Davies 2000), al-
though some research suggests there may be a cardiovascular risk
(Solomon 2008; De Vecchis 2014). Celecoxib is taken orally at
doses between 50 mg and 400 mg daily, divided.
How the intervention might work
Within the immune system, T helper Type 1 (Th1) lymphocytes
stimulateType 1 immunity, whilst ThelperType 2 (Th2) lympho-
cytes stimulate Th2 immunity ( Spellberg 2001). A 2013 study,
as well as others, have observed a clear Th2 shift in schizophre-
nia ( Chiang 2013), therefore we can infer that the Th1 and Th2
immune responses become imbalanced in schizophrenia. Cyclo-
oxygenase-2 inhibitors, such as celecoxib, reduce the synthesis of
pro-inflammatory cytokines, such as Th1-like cytokines. There-
fore, COX-2 inhibitors bring the Th1 and Th2 immune responses
back into balance ( Akhondzadeh 2007).
Secondly, COX-2 inhibitors, such as celecoxib, have also been
found to prevent neuronal death induced by kainic acid (
Akhondzadeh 2007). Kainic acid is an excito-toxin, which is a po-
tent agonist of ionotrophic glutamate receptors ( Yoon 2008). The
glutametergic system has been proposed to be key in both positive
and negative symptoms in schizophrenia, making this mechanism
of action potentially relevant ( Akhondzadeh 2007).
However, Yokota and colleagues examined neuronal COX-2 ex-
pression in the hippocampus of patients with schizophrenia, and
suggested that celecoxib’s mechanism of action in schizophrenia
may involve COX-2 independent actions, such as regulation of
the transcription factor nuclear factor-kappa B ( NF-κB)’s activity,
rather than inhibiting COX-2 ( Yokota 2004).
Why it is important to do this review
Currently available antipsychotic medications used in the treat-
ment of schizophrenia only have partial effectiveness, and can
cause significant, often unpleasant, side effects; additional treat-
ments are often needed ( Girgis 2014). Research indicates that
adding celecoxib to antipsychotic treatment may be a safe and effi-
cacious for schizophrenia, particularly in first-episode schizophre-
nia (Baheti 2013; Girgis 2014;Marini 2016;Müller 2005;Müller
2013; Müller 2016; Riedel 2005; Torrey 2012; Zheng 2017).
However, there is also published literature which does not sup-
port this hypothesis (Andrade 2016; Nitta 2013; Rapaport 2005;
Sommer 2014). Additionally, concerns have been raised over cele-
coxib increasing cardiovascular risk (De Vecchis 2014; Solomon
2008), which contradicts previous research that concluded that
celecoxib did not carry an increased cardiovascular risk compared
to placebo or NSAIDs (White 2007).
Although a meta-analysis investigating the effects of celecoxib as
an add-on treatment for people with schizophrenia was published
very recently in 2017, that review had a number of limitations, in-
cluding the investigation only of randomised, placebo-controlled
trials, and literature searches restricted to English and Chinese
databases only (Zheng 2017). Additionally, five out of the eight
included trials used risperidone as the baseline antipsychotic; the
authors stated that this may result in their findings not being gen-
eralisable to other antipsychotics (Zheng 2017).
Therefore it is important to systematically collate and analyse all
available data from randomised controlled trials to create a high-
quality evidence base for the effects of adding celecoxib to stan-
dard care. We propose to conduct a Cochrane systematic review
which includes a greater variety of studies than previous papers
have done. We will include studies which compare celecoxib ad-
ministered as an add-on treatment with either: antipsychotics,
interventions other than antipsychotics, placebo in combination
with antipsychotics, placebo, or no treatment. We will also search
Cochrane Schizophrenia’s Study-Based Register of Trials, with the
aim of searching a broader range of databases than previous papers
have done. Using these methods we will endeavour to include a
wider range of studies into our review, and thus gain a greater,
higher quality evidence base on the effects and safety of celecoxib
as an add-on treatment for people with schizophrenia.
O B J E C T I V E S
To evaluate the efficacy and safety of celecoxib as an add-on treat-
ment to standard care for people with schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will consider all relevant randomised controlled trials (RCTs).
We will include RCTs whichmeet our inclusion criteria and report
useable data. We will consider trials that are described as ’double
blind’ - in which randomisation is implied - and include or exclude
once we have carried out a sensitivity analysis (see Sensitivity
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analysis). We will exclude quasi-randomised studies, such as those
that allocate the intervention by alternate days of the week.Where
people are given additional treatments as well as celecoxib we will
only include data if the adjunct treatment is evenly distributed
between groups and it is only the celecoxib that is randomised.
Types of participants
Adults, however defined, with a diagnosis (by any means) of
schizophrenia.
We are interested in making sure that information is as relevant
as possible to the current care of people with schizophrenia, so we
aim to highlight the current clinical state clearly (acute, early post-
acute, partial remission, remission), as well as the stage (prodro-
mal, first episode, early illness, persistent), and whether the studies
primarily focused on people with particular problems (for exam-
ple, negative symptoms, treatment-resistant illness).
Types of interventions
1. Experimental interventions
1.1 Celecoxib (alone or in combination with other medication)
plus standard care: any dose, frequency or route of administration.
2. Comparator interventions
2.1 Antipsychotics (alone or combination): any dose, frequency
or route of administration.
2.2 Placebo (active or inactive), or no treatment.
2.3 Other interventions (alone or in combination with antipsy-
chotics, or placebo): any dose, frequency or route of administra-
tion.
We define standard care as the care a participant in the trial would
normally receive.
Types of outcome measures
We aim to divide all outcomes into short term (less than six
months), medium term (seven to 12 months) and long term (over
12 months).
We will endeavour to report binary outcomes recording clear and
clinically meaningful degrees of change (e.g. global impression of
much improved, ormore than 50% improvement on a rating scale,
as defined within the trials) before any others. Thereafter we will
list other binary outcomes and then those that are continuous.
Primary outcomes
1. Global state
1.1 Clinically important change in global state, as defined by in-
dividual studies
1.2 Relapse, as defined by individual studies
2. Mental state
2.1 Clinically important change in specific symptoms: positive,
negative, depression
2.2 Clinically important change in overall mental state, as defined
by individual studies
3. Adverse effects
3.1 Cardiovascular: clinically important change or incidence of
cardiovascular adverse effects, as defined by individual studies
Secondary outcomes
1. Global state
1.1 Any change in global state
1.2 Average endpoint/change score on global state scale
2. Mental state
2.1 Any change in mental state
2.2 Average endpoint/change score on mental state scale
3. Quality of life
3.1 Clinically important change in quality of life, as defined by
individual studies
3.2 Clinically important change in specific aspects of quality of
life, as defined by individual studies
3.3 Any change in quality of life
3.4 Average endpoint/change score on quality of life scale
4. Leaving the study early
4.1 For any reason
4.2 Due to inefficacy
4.3 Due to adverse effect
5. Other adverse effects
5.1 At least one event
5.2 Clinically important change in other adverse effects (e.g. an-
ticholinergic; central nervous system; gastrointestinal; endocrine;
haematological; hepatic; metabolic; movement disorders), as de-
fined by individual studies
5.3 Any change in other adverse effects (e.g. anticholinergic; cen-
tral nervous system; gastrointestinal; endocrine; haematological;
hepatic; metabolic; movement disorders)
5.4. Average endpoint/change score on adverse effect scale
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’Summary of findings’ table
We will use the GRADE approach to interpret findings (
Schünemann 2011); andwill use GRADEpro GDT to export data
from our review to create a ’Summary of findings’ table. These ta-
bles provide outcome-specific information concerning the overall
certainty of evidence from each included study in the compari-
son, the magnitude of effect of the interventions examined, and
the sum of available data on all outcomes we rate as important to
patient care and decision making. We aim to select the following
main outcomes for inclusion in the ’Summary of findings’ table.
• Global state: clinically important change in global state, as
defined by individual studies.
• Mental state: clinically important change in positive
symptoms, as defined by individual studies.
• Mental state: clinically important change in negative
symptoms, as defined by individual studies.
• Mental state: clinically important change in depressive
symptoms, as defined by individual studies.
• Quality of life: clinically important change in quality of life,
as defined by individual studies.
• Adverse effects: clinically important change in
cardiovascular adverse effects, as defined by individual studies.
• Leaving the study early.
If data are not available for these prespecified outcomes but are
available for ones that are similar, we will present the closest out-
come to the prespecified one in the table, but will take this into
account when grading the finding.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
The information specialist will search their register using the fol-
lowing search strategy:
*Celecoxib* in the intervention field of STUDY
In such a study-based register, searching the major concept re-
trieves all the synonyms and relevant studies because all the stud-
ies have already been organised based on their interventions, and
linked to the relevant topics (Shokraneh 2017).
This register is compiled by systematic searches of major resources
(AMED, BIOSIS, CENTRAL,CINAHL,ClinicalTrials.gov, Em-
base, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their
monthly updates, ProQuest Dissertations and Theses A&I and
its quarterly update, Chinese databases (CBM, CNKI, and Wan-
fang) and their annual updates, handsearches, grey literature, and
conference proceedings (see Group’s Module). There are no lan-
guage, date, document type, or publication status limitations for
inclusion of records into the register.
For previous searches, please see Appendix 1.
Searching other resources
1. Reference searching
We will inspect references of all included studies for further rele-
vant studies.
2. Personal contact
We will contact the first author of each included study for infor-
mation regarding unpublished trials. We will note the outcome of
this contact in the ’Included studies’ or ’Studies awaiting classifi-
cation’ tables.
Data collection and analysis
Selection of studies
Review author (AK) will independently inspect citations from the
searches and identify relevant abstracts; review author (RU) will
independently re-inspect a random sample of 20% of these ab-
stracts to ensure reliability of selection. Where disputes arise, we
will acquire the full report for more detailed scrutiny. AKwill then
obtain and inspect full reports of the abstracts or reports meeting
the review criteria; RU will re-inspect a random 20% of these full
reports in order to ensure reliability of selection. Where it is not
possible to resolve disagreement by discussion, we will attempt
to contact the authors of the study. We will summarise the study
selection process using PRISMA 2015.
Data extraction and management
1. Extraction
Review author (AK) will extract data from all included studies.
In addition, to ensure reliability, review author (RU) will inde-
pendently extract data from a random sample of these studies,
comprising 10% of the total. We will attempt to extract data pre-
sented only in graphs and figures whenever possible, but will in-
clude these only if two reviewers independently obtain the same
result. If studies are multi-centre, then where possible we will ex-
tract data relevant to each centre. We will discuss any disagree-
ment and document our decisions. If necessary, we will attempt to
contact study authors through an open-ended request in order to
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obtain missing information or for clarification. CIaire Irving (see
Acknowledgements) will help clarify issues regarding any remain-
ing problems and we will document these final decisions.
2. Management
2.1 Forms
We will extract data onto standard, pre-designed, simple forms
(Cochrane 2014).
2.2 Scale-derived data
We will include continuous data from rating scales only if:
• the psychometric properties of the measuring instrument
have been described in a peer-reviewed journal (Marshall 2000);
• the measuring instrument has not been written or modified
by one of the trialists for that particular trial; and
• the instrument used is a global assessment of an area of
functioning and not sub-scores which are not, in themselves,
validated or shown to be reliable. However there are exceptions;
we will include sub-scores from mental state scales measuring
positive and negative symptoms of schizophrenia.
Ideally the measuring instrument should either be 1) a self-report
or 2) completed by an independent rater or relative (not the thera-
pist). We realise that this is not often reported clearly; we will note
if this is the case or not in the ’Description of studies’ section of
the review.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data: change
data can remove a component of between-person variability from
the analysis; however, calculation of change needs two assessments
(baseline and endpoint) that can be difficult to obtain in unsta-
ble and difficult-to-measure conditions such as schizophrenia. We
have decided primarily to use endpoint data, and only use change
data if the former are not available. If necessary, we will com-
bine endpoint and change data in the analysis, as we prefer to use
mean differences (MDs) rather than standardisedmean differences
(SMDs) throughout (Deeks 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we will apply the following standards
to relevant continuous data before inclusion.
For endpoint data from studies including fewer than 200 partici-
pants, we will do the following.
• When a scale starts from the nite number zero, we will
subtract the lowest possible value from the mean, and divide this
by the standard deviation (SD). If this value is lower than one, it
strongly suggests that the data are skewed and we will exclude
these data. If this ratio is higher than one but less than two, there
is suggestion that the data are skewed: we will enter these data
and test whether their inclusion or exclusion would change the
results substantially. If such data change the results we will enter
them as ’other data’. Finally, if the ratio is larger than two we will
include these data, because it is less likely that they are skewed
(Altman 1996; Higgins 2011).
• If a scale starts from a positive value - such as the Positive
and Negative Syndrome Scale (PANSS), which can have values
from 30 to 210 (Kay 1986) - we will modify the calculation
described above to take the scale starting point into account. In
these cases, skewed data are present if 2 SD > (S − S min), where
S is the mean score and ’S min’ is the minimum score.
Please note: we will enter all relevant data from studies of more
than 200 participants in the analysis, irrespective of the above
rules, because skewed data pose less of a problem in large studies.
We will also enter all relevant change data, as when continuous
data are presented on a scale that includes a possibility of negative
values (such as change data), it is difficult to tell whether or not
data are skewed.
2.5 Common measurement
To facilitate comparison between trials we aim, where relevant, to
convert variables that can be reported in different metrics, such as
days in hospital (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we will make efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS) (Overall 1962),
or the PANSS (Kay 1986), this could be considered as a clinically
significant response (Leucht 2005; Leucht 2005a). If data based
on these thresholds are not available, we will use the primary cut-
off presented by the original authors.
2.7 Direction of graphs
Where possible, we will enter data in such a way that the area to
the left of the line of no effect indicates a favourable outcome for
celecoxib. In situations where this method makes it impossible to
avoid outcome titles with clumsy double-negatives (e.g. ’not un-
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improved’) we will report data where the left of the line indicates
an unfavourable outcome, and note this in the relevant graphs.
Assessment of risk of bias in included studies
Review authors AK and RU will work independently to assess risk
of bias by using criteria described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a). This set of cri-
teria is based on evidence of associations between potential overes-
timation of effect and the level of risk of bias of the article that may
be due to aspects of sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting, or the
way in which these ’domains’ are reported.
If the raters disagree, we will make the final rating by consensus.
Where inadequate details of randomisation and other characteris-
tics of trials are provided, we will attempt to contact the authors
of the studies in order to obtain further information. We will re-
port non-concurrence in quality assessment, but if disputes arise
regarding the category to which a trial is to be allocated, we will
resolve this by discussion.
We will note the level of risk of bias in both the text of the review,
summary ’Risk of bias’ figures, and the ’Summary of findings’
table/s.
Measures of treatment effect
1. Binary data
For binary outcomes we will calculate a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI), as it has been
shown that RR is more intuitive than odds ratios (Boissel 1999),
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). Although the number needed to treat for an ad-
ditional beneficial outcome (NNTB) and the number needed to
treat for an additional harmful outcome (NNTH), with their CIs,
are intuitively attractive to clinicians, they are problematic to cal-
culate and interpret in meta-analyses (Hutton 2009). For binary
data presented in the ’Summary of findings’ table/s we will, where
possible, calculate illustrative comparative risks.
2. Continuous data
For continuous outcomes we will estimate the MD between
groups. We prefer not to calculate effect size measures (i.e. SMD).
However if scales of very considerable similarity are used, we will
presume there is a small difference in measurement, and we will
calculate effect size and transform the effect back to the units of
one or more of the specific instruments.
Unit of analysis issues
1. Cluster-randomised trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Authors often fail to account for
intra-class correlation in clustered studies, leading to a unit of anal-
ysis error whereby P values are spuriously low, CIs unduly nar-
row and statistical significance overestimated (Divine 1992). This
causes type I errors (Bland 1997; Gulliford 1999).
Where clustering has been incorporated into the analysis of pri-
mary studies, we will present these data as if from a non-cluster-
randomised study, but adjust for the clustering effect.
Where clustering is not accounted for in primary studies, we will
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. We will seek to contact first
authors of studies to obtain intra-class correlation coefficients for
their clustered data, and to adjust for this by using accepted meth-
ods (Gulliford 1999).
We have sought statistical advice and have been advised that the
binary data from cluster-randomised trials presented in a report
should be divided by a ’design effect’. This is calculated using the
mean number of participants per cluster (m) and the intra-class
correlation coefficient (ICC): thus design effect = 1 + (m − 1) *
ICC (Donner 2002). If the ICC is not reported we will assume it
to be 0.1 (Ukoumunne 1999).
If cluster-randomised studies have been appropriately analysed and
have taken intra-class correlation coefficients and relevant data
documented in the report into account, synthesis with other stud-
ies will be possible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. This
occurs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the sec-
ond phase. As a consequence, participants can differ significantly
from their initial state at entry to the second phase, despite a wash-
out phase. For the same reason, cross-over trials are not appro-
priate if the condition of interest is unstable (Elbourne 2002). As
both carry-over and unstable conditions are very likely in severe
mental illness, we will only use data from the first phase of cross-
over studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we will present the additional treatment arms in comparisons. If
data are binary we will simply add these and combine within the
two-by-two table. If data are continuous we will combine data
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following the formula in theCochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). Where additional treatment
arms are not relevant, we will not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We choose that, for any particular outcome, should more
than 50% of data be unaccounted for we will not reproduce these
data or use them within analyses. If, however, more than 40% of
those in one arm of a study are lost, but the total loss is less than
60%, we will address this within the ’Summary of findings’ table/
s by down-rating our assessments of the quality of the evidence.
Finally, we will also downgrade our quality assessments within the
’Summary of findings’ table/s should the loss be 25% to 60% in
total.
2. Binary data
In the case where attrition for a binary outcome is between 0% and
40% andwhere these data are not clearly described, wewill present
data on a ’once-randomised-always-analyse’ basis (an intention-
to-treat analysis (ITT)). In this approach, those leaving the study
early are all assumed to have the same rates of negative outcome as
those who completed.We will use the rate of those who stay in the
study - in that particular arm of the trial - and apply this also to
those who did not. We will undertake a sensitivity analysis to test
how prone the primary outcomes are to change when data only
from people who completed the study to that point are compared
to the ITT analysis using the above assumptions.
3. Continuous data
3.1 Attrition
We will use data where attrition for a continuous outcome is be-
tween 0% and 40%, and data only from people who complete the
study to that point are reported.
3.2 Standard deviations
If standard deviations (SDs) are not reported, we will try to obtain
the missing values from the authors. If these are not available,
where there are missing measures of variance for continuous data,
but an exact standard error (SE) and CIs are available for group
means, and either P value or t value are available for differences
in mean, we can calculate SDs according to the rules described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). When only the SE is reported, SDs are calculated
by the formula SD = SE *
√
(n). The Cochrane Handbook for
Systematic Reviews of Interventions presents detailed formulae for
estimating SDs from P, t or F values, CIs, ranges or other statistics
(Higgins 2011). If these formulae do not apply, we will calculate
the SDs according to a validated imputation method which is
based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would be to exclude a given study’s outcome and
thus to lose information.Nevertheless, wewill examine the validity
of the imputations in a sensitivity analysis that excludes imputed
values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present
the results of study completers; others use the method of last ob-
servation carried forward (LOCF); while more recently, methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early, and differences between groups in their reasons for
doing so, is often the core problem in randomised schizophrenia
trials. We will therefore not exclude studies based on the statistical
approach used. However, by preference we will use the more so-
phisticated approaches, i.e. we will prefer to use MMRM or mul-
tiple-imputation to LOCF, and we will only present completer
analyses if some kind of ITT data are not available at all.Moreover,
we will address this issue in the item ’Incomplete outcome data’
of the ’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We will simply in-
spect all studies for participants who are clearly outliers or situa-
tions that we had not predicted would arise and, where found, we
will discuss such situations or participant groups.
2. Methodological heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity.We will sim-
ply inspect all studies for clearly outlying methods which we had
not predicted would arise and discuss any such methodological
outliers.
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3. Statistical heterogeneity
3.1 Visual inspection
We will inspect graphs visually to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I² statistic
We will investigate heterogeneity between studies by considering
the I² statistic alongside the Chi² P value. The I² statistic provides
an estimate of the percentage of inconsistency thought to be due
to chance (Higgins 2003). The importance of the observed value
of I² depends on the magnitude and direction of effects as well
as the strength of evidence for heterogeneity (e.g. P value from
Chi² test, or a confidence interval for I²). We will interpret an I²
estimate greater than or equal to 50% and accompanied by a sta-
tistically significant Chi² statistic as evidence of substantial hetero-
geneity (in accordance with Chapter 9 of the Cochrane Handbook
for Systematic Reviews of Interventions, Deeks 2011). When sub-
stantial levels of heterogeneity are found in the primary outcome,
we will explore reasons for heterogeneity (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in section 10.1 of the Cochrane Handbook for
Systemic reviews of Interventions (Sterne 2011).
1. Protocol versus full study
Wewill try to locate protocols of included randomised trials. If the
protocol is available, we will compare outcomes in the protocol
and in the published report . If the protocol is not available, we
will compare outcomes listed in the methods section of the trial
report with the results that are reported.
2. Funnel plot
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects. We will not use funnel plots for outcomes where there are
ten or fewer studies, or where all studies are of similar size. In other
cases, where funnel plots are possible, we will seek statistical advice
in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies, even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We choose that if I2 is less than 50%, and so there is enough
homogeneity amongst included studies, then we will use a fixed-
effect model for analyses. However, if I2 is greater than or equal to
50%, and so there is substantial heterogeneity amongst included
studies, and if this heterogeneity cannot be explained, we will use
a random-effects model for analyses.
Subgroup analysis and investigation of heterogeneity
We will investigate factors which may be associated with hetero-
geneity by using subgroup analyses as studies allow, for example
in those with a first episode of psychosis and chronic schizophre-
nia. If any of these post-hoc factors show promising links to the
observed heterogeneity, then we will discuss these in this review.
Sensitivity analysis
If there are substantial differences in the direction or precision of
effect estimates in any of the sensitivity analyses listed below, we
will not add data from the lower-quality studies to the results of
the higher-quality trials, but will present these data within a sub-
category. If their inclusion does not result in a substantive differ-
ence, we will retain them in the analyses.
1. Implication of randomisation
If trials are described in some way as to imply randomisation, for
the primary outcomes, we will pool data from the implied trials
with trials that are randomised.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up (see Dealing with missing data) we will compare the find-
ings of the primary outcomes when we use our assumption, with
the findings using completer data only. If there is a substantial
difference, we will report results and discuss them but continue to
employ our assumption.
Where assumptions have to be made regarding missing SDs (see
Dealing with missing data), we will compare the findings on pri-
mary outcomes when we use our assumption, with the findings
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using completer data only. We will undertake a sensitivity analysis
testing how prone results are to change when completer data only
are compared to the imputed data using the above assumption. If
there is a substantial difference, we will report results and discuss
them but continue to employ our assumption.
3. Risk of bias
We will analyse the effects of excluding trials that are at high risk
of bias across one or more of the domains (see Assessment of risk
of bias in included studies) for the meta-analysis of the primary
outcomes.
4. Imputed values
We will also undertake a sensitivity analysis to assess the effects of
including data from trials where we use imputed values for ICC
in calculating the design effect in cluster-randomised trials.
5. Fixed-effect and random-effects
If a random-effects model is used in this review, we will conduct a
sensitivity analysis to assess whether there is a substantial difference
between the results of primary outcomes where a random-effects
model is used for meta-analysis, and where a fixed-effect model is
used.
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A P P E N D I C E S
Appendix 1. Previous searches
Search methods in protocol (2011)
Cochrane Schizophrenia Group Trials Register (October 2010)
We will search the register using the phrase:
[*Celecoxib* OR *Celebrex* OR *SC 58635* OR *SC-58635* in title, abstract and index terms of REFERENCE and intervention of
STUDY]
WH A T ’ S N E W
Date Event Description
30 November 2018 New citation required and minor changes A new author team from The University of Birmingham has un-
dertaken the completion of this review and have completed a new
protocol
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